The new prospectives of statins in combination therapies for ovarian
cancer based on connections of mechanisms
Xinya Zhang
The First Affiliated Hospital of Xi'an Jiaotong University
Author ProfileAbstract
Epithelial ovarian cancer is a disease with the highest mortality rate
among gynecological tumors. After years of studies, despite targeted
drugs and immunotherapies have been developing, their therapeutic
effects are still not ideal. Statins, as lipid-lowering medicines, have
many findings beyond expectation in the fight against cancer, and have
shown promisingly positive results in clinical trials. Actually, statins
cannot be used as a monotherapy to achieve complete remission due to its
efficacy established, but for its great potential lying in effects about
synergism and sensibilization with other drugs, and even the reduction
of side effects of anti-cancer treatment. This review summarizes the
evidence and potential of combining statins with first-line
chemotherapy, bevacizumab, PARP inhibitors and immunotherapy drugs in
the pharmacotherapy of ovarian cancer, and proposes hypothesises about
new combination therapies based on the current mechanisms and theories,
to provide a new perspective to further experimental research and
clinical trials.